Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
154.990
Open
153.690
VWAP
150.07
Vol
1.68M
Mkt Cap
25.78B
Low
148.740
Amount
251.70M
EV/EBITDA(TTM)
11.29
Total Shares
182.20M
EV
38.24B
EV/OCF(TTM)
13.84
P/S(TTM)
1.75
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The Company's Connected Intelligence delivers insights enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real-world insights and services to life science clients. Research & Development Solutions primarily serves biopharmaceutical clients, provides outsourced clinical research and clinical trial services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
4.20B
+6.15%
3.325
+6.58%
4.07B
+4.37%
3.054
+7.52%
3.96B
+3.86%
2.777
+5.19%
Estimates Revision
The market is revising Downward the revenue expectations for IQVIA Holdings Inc. (IQV) for FY2025, with the revenue forecasts being adjusted by -0.44% over the past three months. During the same period, the stock price has changed by -25.84%.
Revenue Estimates for FY2025
Revise Downward
-0.44%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.55%
In Past 3 Month
Stock Price
Go Down
-25.84%
In Past 3 Month
17 Analyst Rating
42.79% Upside
Wall Street analysts forecast IQV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IQV is 212.75 USD with a low forecast of 160.00 USD and a high forecast of 270.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
6 Hold
0 Sell
Moderate Buy
42.79% Upside
Current: 148.990
Low
160.00
Averages
212.75
High
270.00
42.79% Upside
Current: 148.990
Low
160.00
Averages
212.75
High
270.00
HSBC
Rajesh Kumar
Strong Buy
to
Hold
Downgrades
$260 → $160
2025-04-25
Reason
HSBC
Rajesh Kumar
Price Target
$260 → $160
2025-04-25
Downgrades
Strong Buy
to
Hold
Reason
HSBC analyst Sidharth Sahoo downgraded Iqvia to Hold from Buy with a price target of $160, down from $260. The firm adjusted ratings in medical technology and life sciences are quantifying the risk/reward using stagflation, weak macro environment, and recovery scenario analyses. The market is debating whether the recent multiples correction is an opportunity to buy, or if it is the start of a potential recession, the analyst tells investors in a research note. HSBC's analysis of historical sector multiples reveals that the multiples compression might have an additional 20%-25% downside in a stagflation scenario. "We are far from the point where one can argue that these stocks are pricing in a recession," contends HSBC.
Barclays
Luke Sergott
Buy
to
Hold
Downgrades
$235 → $170
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$235 → $170
2025-04-10
Downgrades
Buy
to
Hold
Reason
Barclays downgraded Iqvia to Equal Weight from Overweight with a price target of $170, down from $235. The firm moved to the sidelines on the contract research organizations, citing lower confidence around pharma restructurings based on the pharma-specific tariff overhang. The firm considers the potential reaction of further cost-cutting and budget rightsizing from the "looming pharma-specific tariffs yet to be announced." Pharma can not pass on the tariffs via increased drug pricing, as the Inflation Reduction Act caps Part D price increases at inflation, the analyst tells investors in a research note.
Truist Securities
Jailendra Singh
Strong Buy
Maintains
$263 → $216
2025-04-10
Reason
Truist Securities
Jailendra Singh
Price Target
$263 → $216
2025-04-10
Maintains
Strong Buy
Reason
Truist analyst Jailendra Singh lowered the firm's price target on Iqvia to $216 from $263 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results for Contract Research Organizations, or CROs. The firm is lowering its estimates and price targets for to reflect recent trends and macro uncertainty. Truist states it had previously believed that large pharma market was already halfway through with respect to portfolio reprioritization, but given the funding trends of the past two months and the uncertain pharma industry environment in general, its baseline assumption now sees biotech recovery being pushed out to at least the second half of 2025 and the large pharma market recovery to the first half of 2026, the analyst tells investors in a research note.
Mizuho
Ann Hynes
Buy
Maintains
$242 → $210
2025-04-09
Reason
Mizuho
Ann Hynes
Price Target
$242 → $210
2025-04-09
Maintains
Buy
Reason
Mizuho lowered the firm's price target on Iqvia to $210 from $242 and keeps an Outperform rating on the shares. The firm surveyed 215 physicians over 13 specialties to gauge hospital inpatient and outpatient trends during Q1. The survey suggests both inpatient and outpatient growth trends, while still elevated, appear to have peaked, the analyst tells investors in a research note. Mizuho views the survey as positive for managed care and clinical labs and neutral for hospitals.
Citigroup
Patrick Donnelly
Hold
Maintains
$225 → $210
2025-03-04
Reason
Citigroup
Patrick Donnelly
Price Target
$225 → $210
2025-03-04
Maintains
Hold
Reason
Citi analyst Patrick Donnelly lowered the firm's price target on Iqvia to $210 from $225 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Coming away from earnings, investor appetite for the sector "remains very light," primarily due to ongoing U.S. government pressure, the analyst tells investors in a research note. However, Citi sees pockets of the market to be constructive on, such as bioprocessing, where it believes a recovery is underway. Danaher (DHR) is the firm's top pick.
JP Morgan
Anne Samuel
Buy
Maintains
$240 → $232
2025-02-18
Reason
JP Morgan
Anne Samuel
Price Target
$240 → $232
2025-02-18
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for IQVIA Holdings Inc (IQV.N) is 12.30, compared to its 5-year average forward P/E of 21.10. For a more detailed relative valuation and DCF analysis to assess IQVIA Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Strongly Undervalued
5Y Average PE
21.10
Current PE
12.30
Overvalued PE
24.25
Undervalued PE
17.94
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Strongly Undervalued
5Y Average EV/EBITDA
15.22
Current EV/EBITDA
9.96
Overvalued EV/EBITDA
17.35
Undervalued EV/EBITDA
13.09
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Undervalued
5Y Average PS
2.69
Current PS
1.58
Overvalued PS
3.08
Undervalued PS
2.30
Financials
Annual
Quarterly
FY2025Q1
YoY :
+2.46%
3.83B
Total Revenue
FY2025Q1
YoY :
+0.77%
525.00M
Operating Profit
FY2025Q1
YoY :
-9.97%
262.00M
Net Income after Tax
FY2025Q1
YoY :
-10.26%
1.40
EPS - Diluted
FY2025Q1
YoY :
+13.00%
426.00M
Free Cash Flow
FY2025Q1
YoY :
-2.03%
26.98
Gross Profit Margin - %
FY2025Q1
13.96
FCF Margin - %
FY2025Q1
YoY :
-15.69%
6.50
Net Margin - %
FY2025Q1
YoY :
-9.59%
9.33
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
320.2K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
255.7K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
138.9K
Volume
8
6-9
Months
0.0
Volume
0
0-12
Months
881.6K
Volume
13
Bought
0-3
0
0.0
Volume
Months
3-6
9
880.1K
Volume
Months
6-9
1
2.9M
Volume
Months
0-12
16
487.5K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
8.0K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
32.5K
USD
Months
3-6
1
32.5K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
32.5K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
320.2K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
255.7K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IQV News & Events
Events Timeline
2025-05-06 (ET)
2025-05-06
07:29:02
Iqvia backs FY25 adjusted EPS view $11.70-$12.10, consensus $11.83
2025-05-06
07:26:08
Iqvia reports Q1 adjusted EPS $2.70, consensus $2.63
2025-03-18 (ET)
2025-03-18
15:14:37
Nvidia announces open Llama Nemotron family of models
Sign Up For More Events
Sign Up For More Events
News
1.0
05-07NewsfilterIQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13
9.5
05-07NASDAQ.COMIQVIA (IQV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
4.5
05-06BenzingaStocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?
Sign Up For More News
People Also Watch
LNKB
LINKBANCORP Inc
6.990
USD
-1.69%
FLIC
First of Long Island Corp
12.340
USD
-0.40%
ONIT
Onity Group Inc
37.840
USD
+0.80%
EM
Smart Share Global Ltd
1.100
USD
+1.85%
ONTF
ON24 Inc
4.850
USD
+2.54%
NVX
NOVONIX Ltd
1.260
USD
+2.44%
FVR
FrontView REIT Inc
11.840
USD
+2.16%
HDSN
Hudson Technologies Inc
7.460
USD
-4.36%
BYON
Beyond Inc
4.560
USD
+3.87%
OSUR
OraSure Technologies Inc
2.510
USD
-3.46%
FAQ
What is IQVIA Holdings Inc (IQV) stock price today?
The current price of IQV is 148.99 USD — it has decreased -2.81 % in the last trading day.
What is IQVIA Holdings Inc (IQV)'s business?
What is the price predicton of IQV Stock?
What is IQVIA Holdings Inc (IQV)'s revenue for the last quarter?
What is IQVIA Holdings Inc (IQV)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for IQVIA Holdings Inc (IQV)'s fundamentals?
How many employees does IQVIA Holdings Inc (IQV). have?